S
SkinHealth Systems Inc. (SKIN)
Official siteCONSUMER DEFENSIVE • HOUSEHOLD & PERSONAL PRODUCTS • NASDAQ
$15.05
-1.26 (-7.73%)
Market Cap: $106.26M
Last updated: Nov 17, 2026 at 11:01 AM ET
SkinHealth Systems Inc. (SKIN) Valuation Multiples
SkinHealth Systems (SKIN) trades at 0.3x sales and 1.8x book value. Its forward P/E is 106.4x.
Current Multiples
Its enterprise value is 7.2x its EBITDA. Its free cash flow yield is 23.2%.
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 106.4x |
| Price to sales | 0.3x |
| Price to book | 1.8x |
| EV/EBITDA | 7.2x |
| Price to FCF | 4.3x |
| EV/FCF | 10.1x |
| PEG | N/A |
| FCF yield | 23.2% |
Valuation History
Over the 3 of the 6 year ends shown that have a P/E, its P/E ranged from 353.3x in 2024 to 695.0x in 2025.
| Year end | Price | P/E | P/B |
|---|---|---|---|
| 2025 | $27.80 | 695.0x | 58.0x |
| 2024 | $31.80 | 353.3x | 76.4x |
| 2023 | $62.20 | 365.9x | N/A |
| 2022 | $182.00 | N/A | 150.6x |
| 2021 | $483.20 | N/A | N/A |
| 2020 | $226.20 | N/A | N/A |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About SKIN
What is SKIN's forward P/E ratio?
SkinHealth Systems has a forward P/E ratio of 106.4x.
Is SKIN stock overvalued?
GNG's valuation label for SKIN is Undervalued.
What is SKIN's price to sales ratio?
SkinHealth Systems has a price to sales ratio of 0.3x.
SKIN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors